drugset / Trial / NCT05590195
Effect of PreforPro® on Urinary and Vaginal Health
Phase 3
Unknown
50 enrolled
Jeremy Burton
Deerland Enzymes · collabLondon Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's · collabSt. Joseph's Health Care London · collab
RandomizedParallel-groupDouble-blindTreatment
Summary
This study will investigate the effects of PreforPro® (prebiotic and bacteriophages (LH01-Myoviridae, LL5-Siphoviridae, T4D-Myoviridae, and LL12-Myoviridae, greater \> 6.7 X 107 PFU/gram) on bacterial vaginosis.
Timeline
- Start
- 2024-05-01
- Primary completion
- 2025-03-01
- Completion
- 2025-06-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Preforpro | Other / unclassified | — | Oral |